Delivering the latest trends shaping science, biotech, and healthcare — showcasing work that drives revenue, reputation, and investment for compelling brands — and offering an inside look at the award-winning culture behind it all.
Every strong brand starts with a compelling narrative. But how does a life science company effectively pair validated, peer-reviewed science with a clear, resonant story? Discover what it takes to get the story right in our latest blog.
After decades in biotech, Derek Maetzold launched Castle Biosciences to move beyond a one-size-fits-all approach to cancer care. Featured in an interview with The Pathologist – supported by HDMZ – Derek shares how Castle’s molecular prognostics, such as its DecisionDx-Melanoma and TissueCypher platform for Barrett’s esophagus, are changing outcomes by transforming tumor biology into personalized insights for improved patient outcomes, along with his vision for a future where molecular insights drive nearly every clinical decision.
One of HDMZ’s greatest strengths is the diversity of our people and the wide range of interests they pursue. Discover who we are beyond the workplace and how our hobbies, passions, and talents enhance our culture.
.png?upscale=true&width=1200&upscale=true&name=image%20(48).png)
.png?upscale=true&width=1120&upscale=true&name=image%20(49).png)
.png?upscale=true&width=1120&upscale=true&name=image%20(50).png)
.jpg?upscale=true&width=800&upscale=true&name=events%20post%20(7).jpg)
